1
|
Smeele P, d'Almeida SM, Meiller C, Chéné AL, Liddell C, Cellerin L, Montagne F, Deshayes S, Benziane S, Copin MC, Hofman P, Le Pimpec-Barthes F, Porte H, Scherpereel A, Grégoire M, Jean D, Blanquart C. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis. Mol Cancer 2018; 17:148. [PMID: 30309369 PMCID: PMC6180566 DOI: 10.1186/s12943-018-0891-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Accepted: 09/14/2018] [Indexed: 02/07/2023] Open
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The discovery of soluble biomarkers with diagnostic/prognostic and/or therapeutic properties would improve therapeutic care of MPM patients. Currently, soluble biomarkers described present weaknesses preventing their use in clinic. This study aimed at evaluating brain-derived neurotrophic factor (BDNF), we previously identified using transcriptomic approach, in MPM. We observed that high BDNF expression, at the mRNA level in tumors or at the protein level in pleural effusions (PE), was a specific hallmark of MPM samples. This protein presented significant but limited diagnostic properties (area under the curve (AUC) = 0.6972, p < 0.0001). Interestingly, high BDNF gene expression and PE concentration were predictive of shorter MPM patient survival (13.0 vs 8.3 months, p < 0.0001, in PE). Finally, BDNF did not affect MPM cell oncogenic properties but was implicated in PE-induced angiogenesis. In conclusion, BDNF appears to be a new interesting biomarker for MPM and could also be a new therapeutic target regarding its implication in angiogenesis.
Collapse
Affiliation(s)
- Patrick Smeele
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Sènan Mickaël d'Almeida
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Clément Meiller
- INSERM, UMR-1162, Functional Genomics of Solid Tumors, Université Paris Descartes, Université Paris Diderot, Université Paris 13, Paris, France
| | - Anne-Laure Chéné
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Service d'Oncologie Médicale Thoracique et Digestive, Hôpital Laënnec, CHU de Nantes, Nantes, France
| | - Charly Liddell
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Service d'Anatomie Pathologique, Hôpital Laënnec, CHU de Nantes, Nantes, France
| | - Laurent Cellerin
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Service d'Oncologie Médicale Thoracique et Digestive, Hôpital Laënnec, CHU de Nantes, Nantes, France
| | - François Montagne
- INSERM, UMR-1162, Functional Genomics of Solid Tumors, Université Paris Descartes, Université Paris Diderot, Université Paris 13, Paris, France.,Service de Chirurgie Thoracique, Hôpital Calmette, CHRU Lille, Lille, France
| | - Sophie Deshayes
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Sarah Benziane
- Pulmonary and Thoracic Oncology, CHU de Lille, Univ. Lille, INSERM U1019, CIIL Institut Pasteur de Lille, F59000, Lille, France.,French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN), F59000, Lille, France
| | - Marie-Christine Copin
- Univ. Lille, CHU Lille, Institut de Pathologie et Tumorothèque du C2RC, Avenue Oscar Lambret, F-59000, Lille, France
| | - Paul Hofman
- Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank (BB-0033-00025), University Côte d'Azur, Nice, France
| | - Françoise Le Pimpec-Barthes
- INSERM, UMR-1162, Functional Genomics of Solid Tumors, Université Paris Descartes, Université Paris Diderot, Université Paris 13, Paris, France.,Département de Chirurgie Thoracique et Transplantation pulmonaire, Hôpital Européen Georges Pompidou, Paris, France
| | - Henri Porte
- Service de Chirurgie Thoracique, Hôpital Calmette, CHRU Lille, Lille, France
| | - Arnaud Scherpereel
- Pulmonary and Thoracic Oncology, CHU de Lille, Univ. Lille, INSERM U1019, CIIL Institut Pasteur de Lille, F59000, Lille, France.,French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN), F59000, Lille, France
| | - Marc Grégoire
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Didier Jean
- INSERM, UMR-1162, Functional Genomics of Solid Tumors, Université Paris Descartes, Université Paris Diderot, Université Paris 13, Paris, France
| | | |
Collapse
|